168 related articles for article (PubMed ID: 16193082)
1. Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells.
Xu RH; Pelicano H; Zhang H; Giles FJ; Keating MJ; Huang P
Leukemia; 2005 Dec; 19(12):2153-8. PubMed ID: 16193082
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia.
Li J; Xue L; Hao H; Han Y; Yang J; Luo J
Oncol Rep; 2012 Feb; 27(2):461-6. PubMed ID: 21993902
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis.
Gu L; Gao J; Li Q; Zhu YP; Jia CS; Fu RY; Chen Y; Liao QK; Ma Z
Leukemia; 2008 Nov; 22(11):2091-6. PubMed ID: 18685609
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor activity of 3-bromopyruvate in combination with rapamycin in vivo and in vitro.
Zhang Q; Pan J; Lubet RA; Komas SM; Kalyanaraman B; Wang Y; You M
Cancer Prev Res (Phila); 2015 Apr; 8(4):318-26. PubMed ID: 25644152
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine.
Janus A; Linke A; Cebula B; Robak T; Smolewski P
Anticancer Drugs; 2009 Sep; 20(8):693-701. PubMed ID: 19584709
[TBL] [Abstract][Full Text] [Related]
7. Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma.
Gu L; Xie L; Zuo C; Ma Z; Zhang Y; Zhu Y; Gao J
BMC Cancer; 2015 Jul; 15():529. PubMed ID: 26189041
[TBL] [Abstract][Full Text] [Related]
8. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
[TBL] [Abstract][Full Text] [Related]
9. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
Gibbons JJ; Abraham RT; Yu K
Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
11. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
12. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53.
Mungamuri SK; Yang X; Thor AD; Somasundaram K
Cancer Res; 2006 May; 66(9):4715-24. PubMed ID: 16651424
[TBL] [Abstract][Full Text] [Related]
13. ATP-mediated protein kinase B Akt/mammalian target of rapamycin mTOR/p70 ribosomal S6 protein p70S6 kinase signaling pathway activation promotes improvement of locomotor function after spinal cord injury in rats.
Hu LY; Sun ZG; Wen YM; Cheng GZ; Wang SL; Zhao HB; Zhang XR
Neuroscience; 2010 Sep; 169(3):1046-62. PubMed ID: 20678995
[TBL] [Abstract][Full Text] [Related]
14. Acetaldehyde promotes rapamycin-dependent activation of p70(S6K) and glucose uptake despite inhibition of Akt and mTOR in dopaminergic SH-SY5Y human neuroblastoma cells.
Fang CX; Yang X; Sreejayan N; Ren J
Exp Neurol; 2007 Jan; 203(1):196-204. PubMed ID: 16962100
[TBL] [Abstract][Full Text] [Related]
15. Mammalian target of rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate.
Vanderweele DJ; Rudin CM
Mol Cancer Res; 2005 Nov; 3(11):635-44. PubMed ID: 16317089
[TBL] [Abstract][Full Text] [Related]
16. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
Ma PC; Schaefer E; Christensen JG; Salgia R
Clin Cancer Res; 2005 Mar; 11(6):2312-9. PubMed ID: 15788682
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun.
Itamochi H; Oishi T; Shimada M; Sato S; Uegaki K; Naniwa J; Sato S; Nonaka M; Terakawa N; Kigawa J; Harada T
Clin Cancer Res; 2011 Jul; 17(14):4742-50. PubMed ID: 21610153
[TBL] [Abstract][Full Text] [Related]
18. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
19. Growth inhibitory effect of rapamycin in Hodgkin-lymphoma cell lines characterized by constitutive NOTCH1 activation.
Nagy N; Hajdu M; Márk Á; Király PA; Tóth M; Dankó T; Csóka M; Sebestyén A
Tumour Biol; 2016 Oct; 37(10):13695-13704. PubMed ID: 27473087
[TBL] [Abstract][Full Text] [Related]
20. Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.
Ronellenfitsch MW; Brucker DP; Burger MC; Wolking S; Tritschler F; Rieger J; Wick W; Weller M; Steinbach JP
Brain; 2009 Jun; 132(Pt 6):1509-22. PubMed ID: 19416948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
